Beyond the Hype: The Business of Psychedelics 2.0
Depending on whose advice you take, investing in psychedelics might be the best or worst decision you’ll make. While the internet is awash in click bait promoting the latest celebrity promoting psychedelics, sophisticated investors are doing their homework and discovering under-the-radar opportunities before writing checks. Public or private market investing? Biotech /drug development or services businesses? Psilocybin, Ketamine, or new chemical entities ? Join some of the leading founders from the private sector and thought leaders from the space, as they share their thoughts on where the business of psychedelics is headed, what to look out for, and how to steer clear of the pitfalls.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.
Myriam Barthes
Journey Clinical, Inc
Daniel Goldberg
Palo Santo Fund
Imran Khan
UC Berkeley Center for the Science of Psychedelics
Luke Pustejovsky
Tactogen